News

Fierce Pharma2h
Madrigal touts biomarker data in key MASH population as it works to grow Rezdiffra's reach
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
MyChesCo on MSN7h
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Asianet Newsable on MSN17h
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive ...